Key facts
- Aortyx’s last known valuation is $9.2M (Apr 2021).
- It has raised $19.4M; the latest was Later Stage VC ($15.6M) in Jun 2025.
- Notable investors include European Innovation Council, European Commission, INNVIERTE SICC, Clave (Pamplona), Nara Capital — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Aortyx
- ·The full record, as it builds
Funding rounds
No funding rounds for Aortyx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aortyx
Developer of endovascular devices designed to treat aortic diseases. The company's devices focus on tissue regeneration by mimicking the aorta biomechanical environment and provide a suitable milieu for cell migration and proliferation in a bioresorbable platform that minimizes differences with the natural dynamics of the aorta, enabling professionals to treat vascular diseases efficiently.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Employees
- 19
- Website
- aortyx.com/
- Ownership
- Privately Held (backing)
Aortyx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aortyx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aortyx in its N-PORT filings yet. We sweep new filings monthly.